Work

Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) in patients (pts) with castration-resistant prostate cancer (CRPC): PK, safety and PR testing results from the dose escalation cohort.

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.5051

Authors: Anuradha Jayaram, Karolina Nowakowska, Joaquin Mateo, Daniel Nava Rodrigues, Ruth Riisnaes, Alexander Zukiwski, Stefan Proniuk, Alice Susannah Bexon, Joseph Bisaha, Diletta Bianchini, Zafeiris Zafeiriou, Raquel Perez Lopez, Nina Tunariu, Johann Sebastian De Bono, Gerhardt Attard

Institutions: Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Royal Marsden Hospital, Arno Therapeutics (United States), Bexon Clinical Consulting (United States)

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2479291038

Cites:

Cited by: 1

Related to: 10